HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Aims To Beat 2022 Growth Target While Wrangling Consumer Recession Fears

Executive Summary

Unilever’s confidence is unshaken, though “the threat of recession is starting to impact consumer confidence and change in spending patterns and behaviors,” Unilever CEO Alan Jope acknowledged in a 26 July presentation on fiscal 2022 first-half results.

You may also be interested in...



Unilever Targets Hair Health From Inside-Out With Nutrafol Acquisition

After five years with a minority interest in Nutrafol for “clinically proven hair growth,” Unilever will acquire a majority stake in the supplements brand under undisclosed terms. Nutrafol says its nutraceuticals for men and women – sold through multiple channels including by more than 3,000 physicians – target “the six root causes affecting hair health.”

Unilever's 'Careful' Pricing Strategy Pays Off In Q1

Unilever PLC says pricing is critical to enabling it to continue investing in brands as input cost inflation for the firm in 2022 is expected to reach almost 5bn. The British company increased pricing 8% across its portfolio, which includes skin care brand Dove and vitamin brand Olly, helping drive total underlying sales growth of 7.3% in the first quarter.

Unilever Announces Corporate Restructuring Amid Reports Of Activist Investor Influence

Around 1,500 senior and junior management roles will be cut under Unilever’s announced plan to reshape its corporate matrix, the firm reports on 25 January. The news comes a day after reports that activist investor Nelson Peltz of Trian Fund Management has taken a stake in the business.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel